BRPI0413474A - uso de interferon e ribavirina e kit para uso no tratamento de infecções virais - Google Patents
uso de interferon e ribavirina e kit para uso no tratamento de infecções viraisInfo
- Publication number
- BRPI0413474A BRPI0413474A BRPI0413474-5A BRPI0413474A BRPI0413474A BR PI0413474 A BRPI0413474 A BR PI0413474A BR PI0413474 A BRPI0413474 A BR PI0413474A BR PI0413474 A BRPI0413474 A BR PI0413474A
- Authority
- BR
- Brazil
- Prior art keywords
- ribavirin
- interferon
- provides
- related compound
- antioxidant
- Prior art date
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title abstract 9
- 229960000329 ribavirin Drugs 0.000 title abstract 9
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title abstract 9
- 102000014150 Interferons Human genes 0.000 title abstract 7
- 108010050904 Interferons Proteins 0.000 title abstract 7
- 229940079322 interferon Drugs 0.000 title abstract 7
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003963 antioxidant agent Substances 0.000 abstract 3
- 230000003078 antioxidant effect Effects 0.000 abstract 3
- 239000012528 membrane Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000003223 protective agent Substances 0.000 abstract 3
- 230000036765 blood level Effects 0.000 abstract 2
- 238000011260 co-administration Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 210000004185 liver Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 230000004087 circulation Effects 0.000 abstract 1
- 230000002443 hepatoprotective effect Effects 0.000 abstract 1
- 230000003836 peripheral circulation Effects 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000003253 viricidal effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49482803P | 2003-08-13 | 2003-08-13 | |
| PCT/AU2004/001031 WO2005016370A1 (en) | 2003-08-13 | 2004-08-03 | Method of treating viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413474A true BRPI0413474A (pt) | 2006-10-17 |
Family
ID=34193246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413474-5A BRPI0413474A (pt) | 2003-08-13 | 2004-08-03 | uso de interferon e ribavirina e kit para uso no tratamento de infecções virais |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070202078A1 (https=) |
| EP (1) | EP1660116A4 (https=) |
| JP (1) | JP2007501806A (https=) |
| CN (1) | CN1835765A (https=) |
| AR (1) | AR045263A1 (https=) |
| AU (1) | AU2004264255A1 (https=) |
| BR (1) | BRPI0413474A (https=) |
| CA (1) | CA2535451A1 (https=) |
| CL (1) | CL2004002030A1 (https=) |
| IL (1) | IL173630A0 (https=) |
| NO (1) | NO20060651L (https=) |
| NZ (1) | NZ545159A (https=) |
| RU (1) | RU2371195C2 (https=) |
| WO (1) | WO2005016370A1 (https=) |
| ZA (1) | ZA200601181B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| CA2480826C (fr) | 2002-04-09 | 2012-02-07 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| CN1847256B (zh) * | 2005-04-13 | 2011-06-15 | 长春华普生物技术有限公司 | 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用 |
| WO2006131790A2 (en) * | 2005-06-09 | 2006-12-14 | Flamel Technologies | Oral ribavirin pharmaceutical composition |
| WO2009031918A1 (ru) * | 2007-09-05 | 2009-03-12 | Shatunovsky Nikolai Evgenievic | Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с |
| WO2009046369A2 (en) * | 2007-10-05 | 2009-04-09 | Medtronic, Inc. | Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c |
| PE20110343A1 (es) * | 2008-09-17 | 2011-06-25 | Boehringer Ingelheim Int | Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina |
| US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| US20130295052A1 (en) | 2010-11-19 | 2013-11-07 | Manu Chaudhary | Novel conjugates for targeted drug delivery |
| RU2665638C1 (ru) * | 2017-05-24 | 2018-09-03 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3222259A (en) * | 1963-10-25 | 1965-12-07 | Ethyl Corp | Flare stack with a liquid seal |
| JPS5439143Y2 (https=) * | 1976-04-16 | 1979-11-20 | ||
| US6472373B1 (en) * | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| DK1136075T3 (da) * | 1997-09-21 | 2003-04-28 | Schering Corp | Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| CA2331823A1 (en) * | 1998-05-15 | 1999-11-25 | Schering Corporation | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| JP2002527522A (ja) * | 1998-10-16 | 2002-08-27 | シェリング・コーポレーション | 慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法 |
| AR021876A1 (es) * | 1998-12-18 | 2002-08-07 | Schering Corp | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado |
| US6962717B1 (en) * | 1999-01-29 | 2005-11-08 | Disphar International B.V. | Pharmaceutical compositions |
| AU4463300A (en) * | 1999-04-19 | 2000-11-02 | Schering Corporation | Hcv combination therapy, containing ribavirin in association with antioxidants |
| WO2001081359A1 (en) * | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| EP1326594A2 (en) * | 2000-10-18 | 2003-07-16 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
| US6544497B2 (en) * | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| PL369129A1 (en) * | 2001-09-28 | 2005-04-18 | Intermune, Inc. | Method for treating hepatitis c virus infection in treatment failure patients |
| CA2372987A1 (en) * | 2001-12-11 | 2003-06-11 | Thomas R. Wiseman | Method of disposal of liquid from gas wells |
-
2004
- 2004-08-03 JP JP2006522842A patent/JP2007501806A/ja active Pending
- 2004-08-03 US US10/568,176 patent/US20070202078A1/en not_active Abandoned
- 2004-08-03 ZA ZA200601181A patent/ZA200601181B/en unknown
- 2004-08-03 EP EP04737647A patent/EP1660116A4/en not_active Ceased
- 2004-08-03 CN CNA200480023166XA patent/CN1835765A/zh active Pending
- 2004-08-03 AU AU2004264255A patent/AU2004264255A1/en not_active Abandoned
- 2004-08-03 NZ NZ545159A patent/NZ545159A/en unknown
- 2004-08-03 RU RU2006107566/15A patent/RU2371195C2/ru not_active IP Right Cessation
- 2004-08-03 WO PCT/AU2004/001031 patent/WO2005016370A1/en not_active Ceased
- 2004-08-03 BR BRPI0413474-5A patent/BRPI0413474A/pt not_active IP Right Cessation
- 2004-08-03 CA CA002535451A patent/CA2535451A1/en not_active Abandoned
- 2004-08-09 CL CL200402030A patent/CL2004002030A1/es unknown
- 2004-08-12 AR ARP040102894A patent/AR045263A1/es unknown
-
2006
- 2006-02-09 NO NO20060651A patent/NO20060651L/no not_active Application Discontinuation
- 2006-02-09 IL IL173630A patent/IL173630A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006107566A (ru) | 2007-09-20 |
| NZ545159A (en) | 2009-03-31 |
| AR045263A1 (es) | 2005-10-19 |
| JP2007501806A (ja) | 2007-02-01 |
| CN1835765A (zh) | 2006-09-20 |
| US20070202078A1 (en) | 2007-08-30 |
| CA2535451A1 (en) | 2005-02-24 |
| RU2371195C2 (ru) | 2009-10-27 |
| IL173630A0 (en) | 2006-07-05 |
| CL2004002030A1 (es) | 2005-06-03 |
| WO2005016370A1 (en) | 2005-02-24 |
| EP1660116A4 (en) | 2008-04-30 |
| EP1660116A1 (en) | 2006-05-31 |
| ZA200601181B (en) | 2007-04-25 |
| NO20060651L (no) | 2006-05-02 |
| AU2004264255A1 (en) | 2005-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
| BR0315700A (pt) | Dispositivo médico implantável que incorpora rapamicina deuterada para a aplicação controlada da mesma | |
| BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
| BR0316082A (pt) | Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit | |
| WO2004002999A3 (en) | Modified 2' and 3' -nucleoside produgs for treating flaviridae infections | |
| BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
| HUP9903732A2 (hu) | cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására | |
| BR0314943A (pt) | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes | |
| BR0307975A (pt) | Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina | |
| BRPI0413474A (pt) | uso de interferon e ribavirina e kit para uso no tratamento de infecções virais | |
| WO2004064734A3 (en) | Combination therapies for the treatment of cancer | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| BRPI0512311A (pt) | uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas | |
| BR0311414A (pt) | Agente terapêutico para uma bexiga hiperativa | |
| JP2001510795A5 (https=) | ||
| BR0315573A (pt) | Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica | |
| BRPI0510449A (pt) | uso de formulações de meloxicam em medicina veterinária | |
| AU2002231889A1 (en) | Halogenated composition, method for preparing same and uses thereof | |
| BR0315316A (pt) | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit | |
| BR0309057A (pt) | Formulações lìquidas com baixa dosagem em entecavir e uso | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| Nieto et al. | Comparison of conventional and lipid emulsion formulations of amphotericin B: pharmacokinetics and toxicokinetics in dogs | |
| BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
| CA2385755A1 (en) | Prevention of colorectal cancer | |
| BRPI0416266A (pt) | método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |